|
MK-5684 Clinical Trials
1 actively recruiting trial across 1 location
Also known as: ODM-208
Washington D.C., District of Columbia1 trial
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
MedStar Georgetown Cancer Institute at MedStar Washington Hospital Center ( Site 0026)
Phase 1/2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.